Forthcoming Issue

Peer review articles planned or manuscripts submitted for peer review approval and publication in the forthcoming issues.

Online First

Online First articles have been peer reviewed, accepted for publication and published online; they have not yet been assigned to a journal issue. When an article is published in a journal issue with the assigned page number, it will be removed from the ‘Forthcoming Issue’ page.

Online First articles are copyedited by the science editors and the editorial production team; typeset, proofread and approved by the author(s) before publication. We aim to post each article within six weeks of acceptance and within two weeks after final proofreading approval by the author. Online First articles are in searchable full text, with the initial online publication date included in the final print version.

Articles appearing on the ‘Forthcoming Issue’ page are in the order of the Journal Editorial Sections.  You may also view the abstract by clicking on the article link.

Subscribe now to the print or PDF copy of GaBI Journal to view full information of the following manuscripts*.

Editor’s Letter

Latest features in GaBI Journal, 2018, Issue 3 / Professor Philip D Walson, MD, USA/Germany

Commentary

Medicines regulation in the MENA region and the importance of the World Health Organization’s INN proposal of Biological Qualifier / Peter J Pitts, BA; Michael S Reilly, Esq

Original Research

Extended stability of a biosimilar of trastuzumab (CT-P6) after reconstitution in vials, dilution in polyolefin bags and storage at various temperatures / Victoire Vieillard, PharmD; Professor Alain Astier, PharmD, PhD; Muriel Paul, PharmD

In vitro analytical and antibiotic comparison of generic moxifloxacin against E. coli and S. aureus bacteria strains / Antistio Alviz-Amador, Jairo E Mercado Camargo, Marlene Duran-Lengua

Implementing a treatment registry for a biosimilar: continuous safety surveillance of the biosimilar Bevax® (bevacizumab) in Argentina / Francisco Fernández, MD; Matías Deprati, MD; Patricia Rodríguez Acedo; Eduardo Spitzer, BSc; Alvaro Romera, MD; Nadia Español, BSc

Ongoing activities to influence the prescribing of proton pump inhibitors within the Scottish National Health Service: their effect and implications/ Professor Brian Godman, PhD; Amanj Kurdi, PhD; Holly McCabe, MSc; Sean MacBride-Stewart, MSc; Axel Leporowski, MD; Simon Hurding, MD; Professor Marion Bennie, MSc; Professor Alec Morton, PhD

Review Article

Biocomparable Drugs in Mexico: Challenges and Opportunities in the Treatment of Gaucher Disease / L Carbajal-Rodríguez, MD; M Cerón-Rodríguez, MD; Professor LC Correa-González; A Esquivel-Aguilar, PhD; SJ Franco-Ornelas, MD; JE García Ortiz, PhD; CM Hernández-Guadarrama, MD; JI Navarrete-Martínez; E Terreros-Muñoz, MD; Mexico

The Need for Distinct Nomenclature for Originator and Biosimilar Products / Michael Sarshad; Rosanne Campbell; Peter Pitts; Jacqueline Vanderpuye-Orgle

Meeting Report

First ASEAN educational workshop on regulation and approval of biosimilars/similar biotherapeutic products 2017 – Report / Robin Thorpe, PhD, FRCPath; Elwyn Griffiths, PhD, DSc; Niklas Ekman Ekman, PhD

First GCC Stakeholder Meeting on Approval Process, Interchangeability/ Substitution and Safety of Biosimilars 2017 – Report / Gianluca Trifirò, MD, PhD; Meteb Al-Foheidi, MD, FRCPC; Ali M Alhomaidan, PhD; Ahmed H Aljedai, PharmD, MBA, BCPS, FCCP, FAST; Musaed Abdullah Alkholief, PhD; Mohammad A Alsenaidy, MSc, PhD; Alshamsan, BPharm, RPh, PhD; Tore Kristian Kvien, MD, PhD, Norway

Opinion

‘Biosimilars’ between competition and patient protection: considerations in light of the EU and Italian legal framework / Enrico Adriano Raffaelli; Fausto Massimino

Theory of change: an approach to improve access to medicines in low- and middle-income economies / Mohammad Bashaar; Vijay Thawani; Mohamed Azmi Hassali; Fahad Saleem; Tafseera Hashemi

Abstracted Scientific Content

EU risk-sharing agreements between 2000-2015 / Alice Rolandini Jensen, MSci, GaBI Journal Editor

How does generic drug policy affect market prices / Eleanor Bird, BSc (Hons), GaBI Journal Editor

 

Click here for more details on the educational series.

Contact us for an updated list of editorial topics in forthcoming issues.

*Editorial content may differ from final version of manuscript published in print.

Source URL: http://gabi-journal.net/gabi-journal/forthcoming-issue


Generics and Biosimilars Initiative (GaBI)
Tel: +32 474989572 | Fax: +32 14 583 048